Compare Roundhill Magnificent Seven ETF (MAGS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Smith & Nephew plc — how do they compare? Roundhill Magnificent Seven ETF trades at $73.73 (market cap $5.78B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Smith & Nephew plc for 121 Days on average.
| MAGS | SNN | |
|---|---|---|
Market Cap | $5.78B | $11.10B |
Volume | 4,410,665 | 1,051,703 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $37.17 |
52-Week Low | $55.39 | $26.42 |
Typical Hold Time | 36 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $73.03, down 0.9% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides equal-weighted exposure to the Magnificent Seven tech stocks, though 2026 performance has been muted with a 2% year-to-date gain as the group faces increased competition and AI spending pressures. Recent news highlights both the long-term AI growth theme and near-term underperformance versus the broader market.
The outlook hinges on AI-driven earnings growth from its mega-cap holdings, but concentration risk and shifting investor sentiment pose challenges. Upside potential exists if the Magnificent Seven reassert leadership, while downside risks include prolonged sector rotation and margin compression from heavy capital expenditure.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
